Arecor Therapeutics PLC Exercise of rollover options & Total Voting Rights (0901S)
02 11월 2023 - 12:31AM
UK Regulatory
TIDMAREC
RNS Number : 0901S
Arecor Therapeutics PLC
01 November 2023
Arecor Therapeutics plc
("Arecor" or the "Group")
Exercise of rollover options and Total Voting Rights
Cambridge, UK, 1 November 2023: Arecor Therapeutics plc (AIM:
AREC), the biopharmaceutical company advancing today's therapies to
enable healthier lives, announces that it has issued and allotted
1,332 new Ordinary Shares of 1 pence each in the share capital of
the Company following an exercise of options on 31 October 2023 at
an exercise price of 1 pence per Ordinary Share. The options
exercised were part of the rollover of share options previously
granted under the Arecor Limited EMI Share Option Plan 2018
("Option Rollover"). Details of the Option Rollover are set out in
the Company's Admission Document.
Admission
Following the above transactions, application has been made for
the 1,332 new Ordinary Shares to be admitted to trading on AIM
("Admission") and dealings are expected to commence on, or around,
7 November 2023. The new Ordinary Shares will rank pari passu with
the Company's existing Ordinary Shares.
The total number of Ordinary Shares in issue following Admission
will be 30,626,986. Accordingly, the figure of 30,626,986 may be
used by shareholders as the denominator for the calculations by
which they will determine if they are required to notify their
interest in, or a change to their interest in the Company under the
FCA's Disclosure and Transparency Rules.
-ENDS-
For more information, please contact:
Arecor Therapeutics plc www.arecor.com
Dr Sarah Howell, Chief Executive Tel: +44 (0) 1223 426060
Officer Email: info@arecor.com
Susan Lowther, Chief Financial Officer Tel: +44 (0) 1223 426060
Email: info@arecor.com
Mo Noonan, Communications Tel: +44 (0) 7876 444977
Email: mo.noonan@arecor.com
Panmure Gordon (UK) Limited (NOMAD
and Broker)
Freddy Crossley, Emma Earl (Corporate Tel: +44 (0) 20 7886 2500
Finance)
Rupert Dearden (Corporate Broking)
ICR Consilium
Chris Gardner, David Daley, Lindsey Tel: +44 (0) 20 3709 5700
Neville Email: arecor@consilium-comms.com
Notes to Editors
About Arecor
Arecor Therapeutics plc is a globally focused biopharmaceutical
group transforming patient care by bringing innovative medicines to
market through the enhancement of existing therapeutic products. By
applying our innovative proprietary formulation technology
platform, Arestat(TM), we are developing an internal portfolio of
proprietary products in diabetes and other indications, as well as
working with leading pharmaceutical and biotechnology companies to
deliver enhanced formulations of their therapeutic products. The
Arestat(TM) platform is supported by an extensive patent portfolio.
For further details please see our website, www.arecor.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
TVREASFFEANDFFA
(END) Dow Jones Newswires
November 01, 2023 11:31 ET (15:31 GMT)
Arecor Therapeutics (LSE:AREC)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Arecor Therapeutics (LSE:AREC)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024